Oncology

What we do

The Department of Medical Oncology delivers high-level, evidence-based systemic cancer therapies utilizing state-of-the-art global oncology knowledge.

Working seamlessly across surgical and medical specialties, we design and execute personalized treatment plans based on cancer type, stage, and individual patient health. Whether providing chemotherapy, targeted therapy, immunotherapy, or coordinating surgeries and radiation therapy, our oncologists maintain a holistic overview of each patient’s entire cancer care journey.

Key Strengths & Departmental Highlights

Multidisciplinary / Multimodality Cancer Care: Seamless coordination between Surgical Oncology, Radiation Oncology, and Medical Oncology to deliver the most effective treatment sequence.

Comprehensive Inpatient & Outpatient Integration: Close coordination with Kameda Medical Center in Kamogawa for specialized inpatient admissions, complex infusions, and supportive care.

English Consultations Available: Director Dr. Masaru Oyama provides full medical consultations in English for international patients and expatriates.

Advanced & Refractory Care: Welcoming new diagnoses, second opinions, disease recurrences, and complex or rare malignancies.

Accredited Training Center:

Certified Training Facility by the Japanese Society of Medical Oncology (JSMO)
Certified Training Facility by the Japanese Board of Cancer Therapy

Conditions we handle

We provide comprehensive systemic evaluation, chemotherapy, targeted therapy, and medical management for a wide spectrum of adult malignancies:

Thoracic & Respiratory: Lung Cancer (NSCLC/SCLC), Thymoma/Thymic Carcinoma, Thoracic Sarcoma, Malignant Pleural Mesothelioma.

Gastrointestinal (GI): Esophageal, Gastric (Stomach), Small Intestine, Colorectal, Pancreatic, Gallbladder/Biliary Tract, and Liver Cancers.

Breast & Gynecologic: Breast Cancer, Primary Breast Sarcoma, Ovarian, Uterine/Cervical, Primary Peritoneal Cancers, and Gynecologic Sarcomas.

Sarcomas & Soft Tissue Malignancies: Leiomyosarcoma, Malignant Fibrous Histiocytoma (MFH), Liposarcoma, Angiosarcoma, Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, and Cardiac Tumors.

Urologic & Head/Neck: Kidney (Renal Cell), Bladder, Testicular, Prostate Cancers, Pharyngeal, Laryngeal, and Tongue Cancers.

Brain & Neuro-Oncology: Glioblastoma, Oligodendroglioma, Astrocytoma, and Metastatic Brain Tumors.

Skin, Rare & Special Malignancies: Skin Cancers, Malignant Melanoma, Neuroendocrine Tumors (NET/NEC), and Cancer of Unknown Primary (CUP).

Number of cases

Total Outpatient Consultations: 11,394 patients
Total Inpatient Admissions/Care: 22,719 patient days (or admissions)

(FY2024 Track Record)

Operation results

none

List of Doctors

Chief of Oncology

Yu OYAMA

Subspeciality
Hematology， Oncology， Bone Marrow Transplantation， Autoimmune associated diseases.

Department name	Oncology
Medical School	Nihon University School of Medicine
Special Qualifications	Board Certified Physician of Japanease Society of Internal Medicine Baord Certified Specialist of American Internal Medicine Board Certified Specialist of American Oncology Board Certified Specialist of American Hematology Board Advanced Certified Specialist of Japanese Society of Medical Oncology Baord Tentative instructor of Japan Board of Cancer Therapy
Education & Career	1991.Mar. Graduated from Nihon University School of Medicine 1991.Apr. Residency in Internal Medicine， St，Luke’ｓ International Hospital 1994.May. Clinical Fellow in Hematology/Pulmonary and Critical Care Medicine，Nihon University Hospitalｓ 1996.Jun. Residency in Internal Medicine， Thomas Jefferson University Hospital 1999.Jul. Clinical Fellow in Hematology/Oncology/Stem Cell Transplantation， Northwestern University Medical School 2002.Jul. Clinical Director，Division of Immunotherapy， Assistant Professor，Department of Medicine， Northwestern University Attending Physician，Department of Medicine，Northwestern Memorial Hospital 2006.Oct. Chief ofl Oncology， Kameda Medical Center

Andrology